This article is more than 5 years old. Information may no longer be current.
On Demand Therapeutics to develop novel platform for 'on-demand' drug delivery to posterior segment
Click Here to Manage Email Alerts
MENLO PARK, Calif. — On Demand Therapeutics has announced plans to develop the first multi-reservoir implantable device for laser-activated delivery of drug therapies to the posterior segment, according to a press release from the company.
The injectable, biocompatible, non-resorbable device contains reservoirs designed for drug release in optimized doses. The reservoirs are capable of storing small- or large-molecule drugs that can be released via a standard, noninvasive laser activation procedure. The multiple reservoir system allows for ophthalmologists to control drug delivery by activating specific reservoirs, while unactivated reservoirs remain intact, thereby eliminating the necessity for monthly intravitreal injections, according to the release.
On Demand Therapeutics, which was incorporated as a joint venture between intelligent implant developer MicroCHIPS and venture capital firm InterWest Partners in May 2009, owns an exclusive global license to 60 patents and a number of pending applications regarding ophthalmic drug delivery and related technologies. To date, the company has completed three in vivo proof of concept studies of the implantable device evaluating both small molecule and protein drug delivery.
Follow OSNSuperSite.com
on Twitter.